Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Daewoong Pharmaceutical
Daewoong Pharmaceutical
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
AffyXell expands partnership with GenScript ProBio
As part of the strategic alliance, GenScript has committed to take an equity position in AffyXell at a future funding round
Ingredients
Avacta expands South Korean partnership to include COVID-19 neutralising therapy
Avacta Group has expanded its collaboration and license agreement with Daewoong Pharmaceutical and AffyXell Therapeutics
Ingredients
Affibody announces diabetes option exercise by Daewoong
Affibody will receive a license conversion fee and milestone payments as well as royalties. Further financial details were not disclosed.
Ingredients
Avacta, Daewoong and AffyXell to work on proteins for a range of targets
AffyCell has agreed to provide funds to Avacta for R&D costs of proteins produced by mesenchymal stem cells
Research & Development
Daewoong Pharmaceutical opens Chinese laboratory
Now established in Beijing and Shenyang
Subscribe now